Dr. Michael Mauro on Treatment Discontinuation for CML

Michael Mauro, MD

,

discusses treatment discontinuation for patients with chronic myeloid leukemia (CML)

hematologist and leader of the Myeloproliferative Neoplasms Program, Leukemia Service at Memorial Sloan Kettering Cancer Center, .

TKI

s

Treatment with a can offer a “functional cure,” for some CML patients, aid Mauro. After a period of treatment, some patients may be able to discontinue TKI therapy.

,

If patients have a good response to therapy without any degree of relapse, lower-risk disease at presentation, and a period of time in a deep molecular remission, they may be a candidate for treatment discontinuation. On average about half of the patients that fit that criteria may be able to stop TKI therepy without having significant relapse.

<<<

View more from the 2015 Congress on Hematologic Malignancies